In this study, sPD-1, as an immune checkpoint inhibitor, demonstrated significant effects on immune therapy for lung adenocarcinoma, leveraging the homing capability of BMSCs to target tumor tissues and the immune-regulatory role of IFN-γ (17, 18). This evidence concerns the gene IFNG and lung adenocarcinoma.